drugset / Trial / NCT05661201
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Timeline
- Start
- 2023-04-12
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 8 mg/m2 | Intravenous |
| Subject | Nerofe | Peptide | 48 mg/m2 | Intravenous |
| Subject | Nerofe | Peptide | 96 mg/m2 | Intravenous |
| Subject | Nerofe | Peptide | 192 mg/m2 | Intravenous |
| Subject | Nerofe | Peptide | 288 mg/m2 | Intravenous |